Full Document here:

CONSENSUS STATEMENT

Improving access to care and treatment for Huntington’s Disease patients and families. Sign our petition

Let's get to 500 signs!
Signs

Triplet Therapeutics – Developing Treatment for Huntington’s Disease

Triplet Therapeutics is working on somatic instability as a way of possibly treating Huntingon’s Disease (HD)

During this video, we asked Nessan Bermingham, Brian Bettencourt, Irina Antonijevic & Dr. Anne Rosser about Triplet’s mission and their new approach. They also introduced Triplet’s natural history study of Huntington’s disease, called SHIELD HD.

Find more information

Associations

Find Huntington's Disease
Associations near you

Resources

Different resources
developed for you

Ask our Doctor

Do you have any questions?
Ask our doctor

Events

Find out more about
upcoming events

Previous
Next

NEWS

About the Phase I/II Clinical Program of AMT-130

This HD clinical trial will explore the safety, tolerability, and efficacy signals in 26 total patients with early manifest HD. “We are very pleased with the progress that we continue to make in this Phase 1-2 clinical trial and that we are now administering AMT-130 at the higher dose,” said Ricardo Dolmetsch, Ph.D., president of research  at uniQure.

Full article here

You are kindly invited to join the 1st Huntington’s Disease Meeting for the Arabic Countries, organised by the International Huntington Association 🧡This is the first in a series of educational events dealing with Huntington’s Disease and will take place via Zoom.

Register here for free

Scientists identify precisely how pridopidine works in models of Huntington’s disease.

Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain.

Read the full article here

SUBSCRIBE TO OUR NEWSLETTER